The Charnolosome as a Novel Nanothereranostic Biomarker
Overcoming Future Challenges in Medicine
- 1st Edition - September 27, 2024
- Author: Sushil Sharma
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 5 2 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 5 3 - 1
The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases.
The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.
- Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular level
- Considers the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseases
- Presents future perspectives of the charnolosome in personalized nanotheranostics
Researchers in the field of cell biology, molecular biology, pharmaceutical science, nanomedicine and related areas.Clinicians and students in related areas
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- About the author
- Preface
- Acknowledgments
- Abbreviations
- Definitions
- Introduction
- Part I. General topics
- Chapter 1. Transcriptional regulation of charnolosome through gene/base editing
- Chapter 2. Charnolosome destabilization induces inflammasome activation
- Chapter 3. Charnolosome in charnoly body molecular pathogenesis of gene-manipulated cells and animals
- Chapter 4. Charnolosome and inflammasome in chronic MDR diseases
- Chapter 5. Charnolosome stabilization inhibits inflammasome activation to confer personalized nanotheranostics benefit in chronic MDR diseases
- Chapter 6. Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition
- Chapter 7. Charnolosome stability index (stabilized charnolosome vs. activated inflammasome) determines normal cellular function to remain healthy
- Chapter 8. Charnolosome stability index regulates Charnoly body molecular pathogenesis
- Chapter 9. Nanotheranostic significance of antioxidants in charnolosome detoxification
- Chapter 10. Theranostic significance of charnolosome in personalized nanomedicine
- Chapter 11. Environmental toxins and transcriptional regulation of charnolosome
- Chapter 12. Antioxidants-mediated charnolosome transcriptional regulation in health and disease
- Chapter 13. Mitochondrial bioenergetics, charnolosome, and theranostic potential of antioxidants
- Chapter 14. Cellular, molecular, and genetic significance of metallothioneins as charnolosome modulators
- Chapter 15. Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as charnolosome regulators in health and disease
- Chapter 16. Environmental pollution and metal ion speciation of metallothioneins
- Part II. Metaflammation-specific charnolosome nanotheranostics
- Chapter 17. Metallothioneins as potential charnolopharmacotherapeutics
- Chapter 18. Antioxidants as charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers
- Chapter 19. Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging
- Chapter 20. Charnolosome as a theranostic biomarker in cell therapy and nanomedicine
- Chapter 21. Charnolosome nanotheranostics in malnutrition
- Chapter 22. Charnolosome nanotheranostics in stress
- Chapter 23. Charnolosome nanotheranostics in inflammation
- Chapter 24. Charnolosome nanotheranostics in microbial infection
- Chapter 25. Charnolosome nanotheranostics in ionizing radiation injuries
- Chapter 26. Charnolosome nanotheranostics in congenital diseases
- Chapter 27. Charnolosome nanotheranostics in metabolic diseases
- Chapter 28. Charnolosome nanotheranostics in hyperlipidemia
- Chapter 29. Charnolosome nanotheranostics in obesity
- Chapter 30. Charnolosome nanotheranostics in diabetes
- Chapter 31. Charnolosome in hepatic diseases
- Chapter 32. Charnolosome in GIT diseases
- Part III. Organ-specific charnolosome nanotheranostics of inflammatory diseases
- Chapter 33. Charnolosome nanotheranostics in skin diseases
- Chapter 34. Charnolosome in musculoskeletal diseases
- Chapter 35. Charnolosome nanotheranostics in pulmonary diseases
- Chapter 36. Charnolosome nanotheranostics in cardiovascular diseases
- Chapter 37. Charnolosome nanotheranostics in renal disease
- Chapter 38. Charnolosome nanotheranostics in reproductive system
- Chapter 39. Charnolosome nanotheranostics in polysubstance abuse
- Chapter 40. Charnolosome nanotheranostics in neuropsychiatric diseases
- Chapter 41. Charnolosome nanotheranostics in neurodegenerative diseases
- Chapter 42. Charnolosome nanotheranostics in neurodegenerative synucleinopathies
- Chapter 43. Charnolosome in Parkinson's disease
- Chapter 44. Charnolosome nanotheranostics in Alzheimer disease and other taupathies
- Chapter 45. Charnolosome nanotheranostics in acute ischemic stroke and traumatic brain injury
- Chapter 46. Attenuation of charnolosome-mediated neurodegenerative α-synucleinopathies by antioxidants
- Chapter 47. Charnolosome as a novel nanotheranostic biomarker of aging
- Chapter 48. Charnolosome nanotheranostics in inflammatory diseases
- Chapter 49. Charnolosome nanotheranostics in autoimmune diseases
- Chapter 50. Charnolosome nanotheranostics in cancer (with special reference to multidrug-resistant malignancies)
- Chapter 51. Charnolosome nanotheranostics in infectious diseases (With Special Reference to COVID-19 infection)
- Chapter 52. Charnolosome nanotheranostics in Mitochondrial Nanomedicine
- Chapter 53. Charnolosome-based disease-specific nanotherapeutics
- Chapter 54. Physiological, biochemical, pharmacological, and genetic manipulations of charnolosome in personalized nanotheranostics of chronic MDR diseases
- Chapter 55. Transcriptional and translational regulation of charnolosome in multidrug-resistant malignancies and other chronic diseases
- Chapter 56. Future prospects of charnolosome in evidence-based personalized nanotheranostics
- Index
- No. of pages: 968
- Language: English
- Edition: 1
- Published: September 27, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443217524
- eBook ISBN: 9780443217531
SS
Sushil Sharma
Academic Dean Sushil Sharma works at the American International School of Medicine in Georgetown, Guyana, USA.
Affiliations and expertise
Academic Dean, American International School of Medicine, Georgetown, Guyana, USARead The Charnolosome as a Novel Nanothereranostic Biomarker on ScienceDirect